Section 5 of 6
Economic information and modeling report
3 evidence topics · 1 source
Modeling overview
Summary
The Dutch horizon scan provides provisional cost and population estimates rather than a comparative budget impact model. It lists an expected annual cost below €16,500 per patient, an expected annual population of 60 to 80 patients, and potential total annual expenditure of €1,155,000. The document states that the price is not yet known and that costs may be comparable to spesolimab. These estimates are not an announced acquisition price and do not establish incremental expenditure or savings relative to another treatment.
Netherlands: expected cost per patient per year
Netherlands: projected patient volume and total annual expenditure
| Parameter | Reported value |
|---|---|
| Expected annual patient volume: lower estimate | “60” |
| Expected annual patient volume: upper estimate | “80” |
| Potential total annual expenditure, euros | “1,155,000.00” |
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.